References
- Laversuch C. J., Collins D. A., Charles P. J., Bourke B. E. Sulphasalazine‐induced autoimmune abnormalities in patients with rheumatic disease. Br J Rheumatol 1995; 34: 435–9
- Choi H. K., Merkel P. A., Walker A. M., Niles J. L. Drug‐associated antineutrophil cytoplasmic antibody‐positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis Rheum 2000; 43: 405–13
- Gunnarsson I., Kanerud L., Pettersson E., Lundberg I., Lindblad S., Ringertz B. Predisposing factors in sulphasalazine‐induced systemic lupus erythematosus. Br J Rheumatol 1997; 36: 1089–94
- Choi H. K., Slot M. C., Pan G., Weissbach C. A., Niles J. L., Merkel P. A. Evaluation of antineutrophil cytoplasmic antibody seroconversion induced by minocycline, sulfasalazine, or penicillamine. Arthritis Rheum 2000; 43: 2488–92
- Gordon M. M., Porter D. R., Capell H. A. Does sulphasalazine cause drug induced systemic lupus erythematosus? No effect evident in a prospective randomised trial of 200 rheumatoid patients treated with sulphasalazine or auranofin over five years. Ann Rheum Dis 1999; 58: 288–90
- Sihvonen S., Korpela M., Mustila A., Mustonen J. The predictive value of rheumatoid factor isotypes, anti‐cyclic citrullinated peptide antibodies, and antineutrophil cytoplasmic antibodies for mortality in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 2089–94
- Douglas G., Bird K., Flume P., Silver R., Bolster M. Wegener's granulomatosis in patients with rheumatoid arthritis. J Rheumatol 2003; 30: 2064–9
- Chinoy H., McKenna F. Wegener's granulomatosis and rheumatoid arthritis overlap. Rheumatology (Oxford) 2002; 41: 588–9
- Drayer D. E., Reidenberg M. M. Clinical consequences of polymorphic acetylation of basic drugs. Clin Pharmacol Ther 1977; 22: 251–8
- Gunnarsson I., Nordmark B., Hassan B. A., Grondal G., Larsson P., Forslid J., et al. Development of lupus‐related side‐effects in patients with early RA during sulphasalazine treatment – the role of IL‐10 and HLA. Rheumatology (Oxford) 2000; 39: 886–93
- Rodenburg R. J., Ganga A., van Lent P. L., van de Putte L. B., van Venrooij W. J. The antiinflammatory drug sulfasalazine inhibits tumor necrosis factor alpha expression in macrophages by inducing apoptosis. Arthritis Rheum 2000; 43: 1941–50
- Habens F., Srinivasan N., Oakley F., Mann D. A., Ganesan A., Packham G. Novel sulfasalazine analogues with enhanced NF‐kB inhibitory and apoptosis promoting activity. Apoptosis 2005; 10: 481–91
- Akahoshi T., Namai R., Sekiyama N., Tanaka S., Hosaka S., Kondo H. Rapid induction of neutrophil apoptosis by sulfasalazine: implications of reactive oxygen species in the apoptotic process. J Leukoc Biol 1997; 62: 817–26
- Ralston D. R., Marsh C. B., Lowe M. P., Wewers M. D. Antineutrophil cytoplasmic antibodies induce monocyte IL‐8 release. Role of surface proteinase‐3, alpha1‐antitrypsin, and Fcgamma receptors. J Clin Invest 1997; 100: 1416–24
- Jagiello P., Gencik M., Arning L., Wieczorek S., Kunstmann E., Csernok E., et al. New genomic region for Wegener's granulomatosis as revealed by an extended association screen with 202 apoptosis‐related genes. Hum Genet 2004; 114: 468–77